Insertional Achilles Tendinopathy
Investigational use for insertional Achilles tendinopathy distinct from mid-substance disease; weaker case-series response.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for insertional Achilles tendinopathy. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
- What evidence exists?
- Tier C (investigational). There are no published controlled trials for insertional Achilles tendinopathy specifically. Evidence-based care: heel lifts and supportive footwear, activity modification, eccentric calf strengthening modified for insertional disease (the strongest tendinopathy evidence), heavy slow-resistance training, NSAIDs for short-term symptoms, extracorporeal shock-wave therapy (modest RCT support), and (refractory) PRP, ultrasound-guided needling, or surgical debridement with Haglund deformity excision. Corticosteroid injection is generally avoided because of rupture risk.
- Main risks
- Bleeding from each bite site for 6 to 24 hours after detachment
- Bruising over the posterior heel or distal Achilles for 5 to 10 days
- Local skin or, rarely, Aeromonas hydrophila infection
- Allergic reaction to leech saliva (uncommon)
- RISK if placed directly on the Achilles tendon - direct trauma may precipitate rupture
- Septic bursitis if a contaminated bite penetrates near the retrocalcaneal bursa
- Worsening tendon pain from local irritation
- Delay of evidence-based heavy slow-resistance training - the highest-evidence intervention
- Who should not consider this
- Patients with suspected partial or complete Achilles tendon rupture (surgical emergency)
- Patients on fluoroquinolone antibiotics (tendon rupture risk)
- Patients with diabetes, peripheral arterial disease, or impaired protective sensation
- Patients with recent corticosteroid injection at the site (within 4 weeks)
- Patients who have not completed at least 12 weeks of eccentric calf strengthening modified for insertional disease
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients with active dermatitis or broken skin over the posterior heel
- What to ask your clinician
- Have I had ultrasound or MRI to characterize the tendon and rule out partial or complete tear?
- Have we ruled out retrocalcaneal bursitis, Haglund deformity, or systemic enthesitis (spondyloarthropathy)?
- Have I completed a structured 12-week eccentric or heavy slow-resistance training program modified for insertional disease?
- Have I tried heel lifts, supportive footwear, and activity modification?
- Have I tried ESWT, and what is its evidence vs. this investigational option?
- Where exactly will leeches be placed - confirm placement is adjacent to (NOT directly on) the Achilles tendon?
- What is the Aeromonas-prevention protocol?
- When to seek urgent care
- Sudden pop, severe pain, and inability to plantarflex the foot (Achilles rupture - surgical emergency)
- Acute severe ankle swelling with warmth (possible septic bursitis)
- Calf swelling, redness, or warmth (possible DVT)
- Bleeding from a bite site lasting more than 24 hours
- Fever, chills, or spreading redness at the bite site
- Hives, facial or throat swelling, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for insertional Achilles tendinopathy.
- No controlled trials support efficacy specifically for insertional disease.
- It does not replace eccentric or heavy slow-resistance training, which has the strongest tendinopathy evidence.
- It does not address Achilles rupture, which is a surgical emergency.
- Direct trauma to the tendon may precipitate rupture - placement must be adjacent, not over the tendon.
Safety cross-references
Clinical Profile
- Category
- musculoskeletal
- ICD-10
- M76.61, M76.62, M77.51
- Safety tier
- low
Evidence Summary
Insertional Achilles tendinopathy (often coexisting with Haglund deformity and retrocalcaneal bursitis) responds less well than mid-substance disease to all conservative modalities. No controlled clinical trial or case series of leech therapy for Achilles tendinopathy has been published; use is investigational and mechanistic only, with a speculative local anti-inflammatory rationale on the enthesopathy. Eccentric loading with a reduced dorsiflexion arc and shockwave therapy remain first-line, and surgical debridement is considered after roughly six months of conservative failure.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Khan MA et al. (2021), n=16
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Acute Achilles rupture (surgical)
- Recent local corticosteroid injection (<4 weeks)
- Active retrocalcaneal bursitis with infection
Related Conditions
Knee Osteoarthritis
Off-label use with three RCTs showing pain and function improvement comparable to NSAID gel at 3 months in mild-to-moderate symptomatic knee OA.
Thumb Carpometacarpal (CMC-1) Osteoarthritis
Off-label use with RCT evidence: single-session leech therapy reduces pain and improves function in CMC-1 (basal thumb) OA at 8 weeks.
Lateral Epicondylitis (Tennis Elbow)
Off-label use with two RCTs showing significant pain reduction at 7-12 weeks compared to topical NSAID and conventional physiotherapy.
Plantar Fasciitis
Off-label use with one RCT showing significant heel pain reduction at 6 weeks compared to conservative care.